BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21116247)

  • 1. Cognition: the ultimate brain function.
    Robbins TW
    Neuropsychopharmacology; 2011 Jan; 36(1):1-2. PubMed ID: 21116247
    [No Abstract]   [Full Text] [Related]  

  • 2. Gut feelings about irritable bowel syndrome.
    Stahl SM
    J Clin Psychiatry; 2001 Aug; 62(8):590-1. PubMed ID: 11561928
    [No Abstract]   [Full Text] [Related]  

  • 3. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition?
    Stahl SM
    J Clin Psychiatry; 2008 Nov; 69(11):1673-4. PubMed ID: 19200426
    [No Abstract]   [Full Text] [Related]  

  • 4. Psychotomimetic effects of kappa opioid receptor agonists.
    White KL; Roth BL
    Biol Psychiatry; 2012 Nov; 72(10):797-8. PubMed ID: 23083945
    [No Abstract]   [Full Text] [Related]  

  • 5. Affective cognition and its disruption in mood disorders.
    Elliott R; Zahn R; Deakin JF; Anderson IM
    Neuropsychopharmacology; 2011 Jan; 36(1):153-82. PubMed ID: 20571485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verbal memory.
    Sumiyoshi T
    Handb Exp Pharmacol; 2015; 228():237-47. PubMed ID: 25977085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Docosahexaenoic Acid (DHA) on Cognitive Functions in Psychiatric Disorders.
    Ciappolino V; Mazzocchi A; Botturi A; Turolo S; Delvecchio G; Agostoni C; Brambilla P
    Nutrients; 2019 Apr; 11(4):. PubMed ID: 30986970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders?
    Soczynska JK; Kennedy SH; Chow CS; Woldeyohannes HO; Konarski JZ; McIntyre RS
    Expert Opin Investig Drugs; 2008 Jun; 17(6):827-43. PubMed ID: 18491985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropharmacological modulation of cognition.
    Chamberlain SR; Müller U; Robbins TW; Sahakian BJ
    Curr Opin Neurol; 2006 Dec; 19(6):607-12. PubMed ID: 17102701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular signalling pathways and mood disorders.
    Fišar Z; Hroudová J
    Folia Biol (Praha); 2010; 56(4):135-48. PubMed ID: 20974046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive enhancers: potential strategies and experimental results.
    Wenk GL; Olton DS
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13 Suppl():S117-39. PubMed ID: 2694226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strains of rodents and the pharmacology of learning and memory.
    Ammassari-Teule M; Castellano C
    Neural Plast; 2004; 11(3-4):205-16. PubMed ID: 15656269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?
    Jeon WJ; Dean B; Scarr E; Gibbons A
    Curr Neuropharmacol; 2015; 13(6):739-49. PubMed ID: 26630954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug action.
    Jentsch JD; Roth RH; Taylor JR
    Prog Brain Res; 2000; 126():433-53. PubMed ID: 11105661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reward system of the brain.
    Routtenberg A
    Sci Am; 1978 Nov; 239(5):154-64. PubMed ID: 32618
    [No Abstract]   [Full Text] [Related]  

  • 16. Animal models of cognitive function.
    Decker MW
    Crit Rev Neurobiol; 1995; 9(4):321-43. PubMed ID: 8829849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emotional brain: combining insights from patients and basic science.
    Rosen HJ; Levenson RW
    Neurocase; 2009 Jun; 15(3):173-81. PubMed ID: 20183547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurogenesis and exercise: past and future directions.
    van Praag H
    Neuromolecular Med; 2008; 10(2):128-40. PubMed ID: 18286389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postischemic administration of HLDF-6 peptide ameliorates cognitive dysfunction and brain damage induced by chronic cerebral ischemia in rats.
    Kostanyan IA; Storozheva ZI; Semenova NA; Lipkin VM
    Dokl Biol Sci; 2009; 428():418-22. PubMed ID: 19994779
    [No Abstract]   [Full Text] [Related]  

  • 20. Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.
    Ortiz R; Ulrich H; Zarate CA; Machado-Vieira R
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Mar; 57():117-31. PubMed ID: 25445063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.